Philipson in Forbes: Is Disneyland the Future of Personalized Medicine?
In Tomas Philipson’s latest Forbes.com commentary, he wonders whether the pricing system used by Disneyland and other amusement parks is a concept applicable to personalized medicine.
To read the complete commentary, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.